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ABSTRACT
Heart failure with preserved ejection fraction (HFpEF) accounts for at least half of all patients 
with heart failure (HF) and is projected to be the most common form of HF in the near 
feature. HFpEF, characterized by high morbidity and mortality, poses an enormous medical 
and societal burden and lacks evidence-based therapies. Hence, HFpEF has been recognized 
as the greatest unmet need in cardiovascular medicine. HFpEF is a heterogenous syndrome 
presenting as several different clinical phenotypes. Among these, metabolic alteration-
driven HFpEF—i.e. cardiometabolic HFpEF—is emerging around the globe as the most 
prevalent form of HFpEF. Pathophysiological mechanisms of cardiometabolic HFpEF are 
still incompletely understood. However, recent advances in the preclinical modeling of the 
syndrome, coupled with better definition of its clinical presentations and analysis of human 
HFpEF myocardial specimens, have unveiled metabolic disturbances and inflammatory 
burden as 2 key drivers of HFpEF pathophysiology. Here, we summarize evidence in support 
of a cardiometabolic phenotype of HFpEF and discuss the pivotal biological mechanisms 
underlying this syndrome in the hope of informing more efficacious therapeutic approaches 
in the future.
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Inflammation
INTRODUCTION
The clinical syndrome of heart failure (HF) is a growing public health challenge with an 
estimated prevalence of >30 million individuals worldwide, including >6 million in the 
United States alone, contributing in 2017 to 1 in 8 deaths.1-3 Currently, 2 major phenotypes of 
HF are recognized: HF with reduced ejection fraction (HFrEF) and HF with preserved ejection 
fraction (HFpEF).4,5 Importantly, over the last decade, the growth in incidence and prevalence 
for the 2 types of HF have not been the same. HFpEF has been rising by 10% relative to HFrEF 
and this gap is expected to increase further in coming years owing to aging of the population 
and the increased prevalence of predisposing conditions associated with the development of 
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Cardiometabolic HFpEF: Mechanisms 
and Therapies
HFpEF, particularly obesity, metabolic syndrome, and diabetes.6,7 Simply put, HFpEF is the 
most common form of HF, affecting more than two-thirds of individuals with HF (Figure 1).
Despite similar clinical presentations, the totality of evidence supports a model in which 
HFpEF and HFrEF are 2 mechanistically distinct pathophysiological entities with the 
transition from HFpEF to HFrEF being a rare event.6,8 In support of the pathophysiological 
distinction between HFrEF and HFpEF is the fact that cornerstone therapies effective in 
HFrEF have failed to improve clinical outcomes in patients with HFpEF.9 As a result, no 
effective therapies are available to positively impact survival of patients with HFpEF.
The heterogeneity of the clinical manifestations of HFpEF, coupled with the complexities of 
its pathophysiological mechanisms, stem from the fact that HFpEF cannot be considered a 
single disease. Rather, HFpEF is a heterogenous syndrome in which multiple comorbidities 
differentially contribute to the overall clinical presentation. Indeed, within the HFpEF 
syndrome, it is possible to distinguish phenotypes that emerge from different predisposing 
conditions and have different responses to treatment.7,8,10 As mentioned above, the 
global spread of obesity and metabolic syndrome have shaped the HFpEF syndrome, 
with obesity and metabolic syndrome, and often type 2 diabetes, being present in most 
patients with HFpEF.11-13 These conditions are now understood to be major drivers of HFpEF 
pathophysiology. Importantly, different HFpEF phenotypes also have distinct geographic 
distributions. In fact, hypertensive, stiff, hypertrophic hearts in lean HFpEF patients are 
becoming rare in the US and Europe, but they are common in Asia.14 Nevertheless, a shift 
toward increased adiposity is also occurring in the Asian HFpEF population.
The clinical heterogeneity of HFpEF is reflected in the complexity of preclinical modeling of 
the syndrome to unravel its underlying mechanisms. As elucidation of pathophysiological 
mechanisms underlying any disease relies on the availability of animal and cellular 
models, the existence of multiple phenotypes of clinical HFpEF requires highly integrated 
experimental approaches to decipher the biology of the syndrome. Here, we discuss basic 
and translational data focusing on the most common form of HFpEF, cardiometabolic 
HFpEF, the effects of lipid mishandling on inflammatory cues, and potential strategies to 






















Figure 1. Schematic representation of the projected increases in prevalence of HFpEF over HFrEF owing to the 
increasing spread of obesity and other metabolic alterations. 
CAD = coronary artery disease; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with 
reduced ejection fraction.
HFpEF AS A RESULT OF CHRONIC CARDIOMETABOLIC 
STRESS
Cardiometabolic stress contributes to adverse outcomes in many cardiovascular diseases, 
and obesity represents a major risk factor for both HFrEF and HFpEF. However, obese 
subjects have higher risk of developing HFpEF as compared with HFrEF, and obese HFpEF 
patients present with worse functional parameters as well as increased risk of poor 
outcomes compared to their lean HFpEF counterparts.15 Presently, the average body mass 
index of HFpEF patients in the US is >35 kg/m2. The high prevalence of obesity in the 
HFpEF population is associated with other detrimental sequalae. Obese HFpEF subjects 
often present with type 2 diabetes or glucose intolerance and hypertension (Figure 2). This 
constellation of cardiometabolic alterations in HFpEF subjects affects not only the heart 
but also the vasculature, the skeletal muscle, contributing to HFpEF-associated exercise 
intolerance, and indeed the majority of organ systems, highlighting that HFpEF is a global, 
systemic condition.16
Among diseases triggered/associated with metabolic alterations, HFpEF is the most prevalent 
and deadly. HFpEF is a syndrome with high morbidity and mortality, with a 35% 2-year rate of 
HF hospitalization and 2-year mortality of 14%.6 The high mortality in HFpEF is also related 
to the fact that no evidence-based therapies are currently available for the syndrome. Despite 
the fact that amelioration of cardiometabolic parameters through behavioral or nutritional 
strategies (e.g. exercise training, diet, or bariatric surgery) have demonstrated that HFpEF 
clinical outcomes can be favorably modified, lack of targeted pharmacological therapies 
represents a major challenge in the field.
Another line of evidence in support of the pathogenetic role of cardiometabolic alterations 
in HF pathophysiology emerges from the recent, major clinical benefit observed in HFrEF 













Figure 2. Schematic depicting the combination of cardiometabolic stress driving HFpEF. HFpEF main 
pathophysiological mechanisms and their potential therapeutic strategies. 
HFpEF = heart failure with preserved ejection fraction; iNOS = inducible nitric oxide synthase; NAD+ = 
nicotinamide adenine dinucleotide.
(SGLT2i).17 These drugs improve metabolic parameters and provide strikingly positive effects 
on cardiovascular outcomes in patients with HF even in the absence of diabetes.18 Even 
though mechanisms of SGLT2i-afforded cardioprotection remain elusive, these agents are 
presently being tested in large HFpEF clinical trials.19 In summary, multiple lines of clinical 
and epidemiological evidence support the role of cardiometabolic stress as a major driver 
of HFpEF, suggesting that targeting cardiometabolic alterations represents a therapeutic 
strategy with promise.
MECHANISMS OF CARDIOMETABOLIC ALTERATIONS IN 
HFpEF: METABOLISM AND INFLAMMATION
Visceral adiposity contributes to HFpEF pathogenesis via multiple mechanisms. Excess 
adipose tissue increases mechanical strain on the heart and indirectly promotes and 
amplifies other comorbidities such as insulin resistance and hypertension. In addition to 
this, it is now becoming clear that adipose tissue, a highly metabolically active tissue, exerts 
detrimental effects on cardiometabolic health by directly influencing cardiac metabolism, 
immune activation and, in general, dictating inflammatory responses in HFpEF.20,21 Obesity 
and metabolic stress induce a systemic pro-inflammatory state and dysregulation of 
inflammatory and immune responses are now recognized as culprit mechanisms in HFpEF 
pathophysiology (Figure 2).
We and others have demonstrated that inflammation-dependent oxidative and nitrosative 
stress drive HFpEF, and recruitment of inflammatory cells has been recognized in 
endomyocardial biopsies from HFpEF patients.22-25 Importantly, metabolic alterations 
promote a pro-inflammatory state in HFpEF, a condition termed metabolic inflammation, 
or meta-inflammation, to describe the chronic low-grade inflammatory state emerging 
in response to metabolic cues. Obesity is marked by expansion of adipose tissue and 
consequent increased release of chemokines that initiates recruitment of immune cells. For 
example, obesity is associated with polarization of macrophages toward a pro-inflammatory 
phenotype (Figure 2). Indeed, lipids act as inflammatory molecules and participate in the 
recruitment of immune cells in the HFpEF myocardium.
Local cardiac adipose tissue can also contribute to myocardial inflammation in HFpEF. 
Expansion and increased secretion of cytokines from epicardial adipose tissue (EAT) has 
been proposed as a mechanism contributing to meta-inflammation in HFpEF.26 Clinical 
evidence in support of this model exists, but experimental evidence is lacking, and 
mechanisms of EAT-induced myocardial dysfunction in HFpEF are still unknown. Whereas 
these findings highlight HFpEF as a chronic cardiovascular inflammatory syndrome, the role 
and extent of specific immune cells and mediators in metainflammatory pathways in HFpEF 
remain largely unknown.
Metabolic syndrome-related lipid dysregulation contributes to myocardial alterations in 
HFpEF not only through regulation of inflammatory effects but also by directly affecting 
cardiomyocyte metabolism. A hallmark of cardiac metabolism is its metabolic flexibility, 
i.e. the ability to utilize different sources of fuel efficiently depending of environmental 
changes.27,28 A paradigmatic example of the heart's ability to pivot among energetic 
substrates under stress conditions occurs when myocardial oxygen levels drop. Under 




oxidation provides the majority of energy equivalents to maintain cardiomyocyte 
homeostasis. In HF, myocardial oxygen levels are reduced and cardiomyocyte metabolism 
shifts toward increased utilization of carbohydrates instead of FAs in an effort to maintain 
cardiac efficiency.29,30 Several lines of clinical and experimental evidence suggest that 
myocardial energy metabolism is impaired in HFpEF. We have recently demonstrated that in 
preclinical cardiometabolic HFpEF, cardiomyocytes accumulate lipids resulting in impaired 
myocardial utilization of lipids as an energy source, culminating in lipotoxicity.22 Our 
findings go on to show that cardiac lipotoxicity in HFpEF triggers mitochondrial alterations 
coupled with reduction in the oxidation of FAs and impaired myocardial energetics. Even 
though more work is needed to elucidate molecular pathways of lipid alterations in HFpEF, it 
is clear that lipotoxicity contributes to HFpEF pathogenesis, and elucidation of its molecular 
determinants might reveal novel therapeutic targets in the syndrome.
THERAPEUTIC APPROACHES IN CARDIOMETABOLIC 
HFpEF
HFpEF is a syndrome lacking effective therapies. Despite its prevalence and trajectory, 
pointing to HFpEF as the most common form of HF, there are no efficacious therapeutic 
options to treat the millions of people with the syndrome. Different from HFrEF, for which 
progress obtained with pharmacological and non-pharmacological therapeutic approaches 
has resulted in a significant increase in survival of patients, HFpEF survival has not improved 
in recent decades. Cornerstones of HFrEF therapy, such as neurohormonal blockade, have 
failed to provide benefit in HFpEF. Indeed, the entire strategy of repurposing HFrEF therapies 
to treat HFpEF patients has failed to date, lending additional credence to the notion that 
HFrEF and HFpEF are pathophysiologically distinct. As a consequence, targeted and specific 
therapies to treat HFpEF are required. Indeed, it has been correctly stated that HFpEF 
represents the greatest unmet need in cardiovascular medicine. We submit that targeting 
metabolic and inflammatory pathways represents a strategy with promise (Figure 2). 
However, translating this knowledge into effective therapeutic approaches poses challenges.
Anti-inflammatory approaches
Directly targeting inflammation for therapeutic benefit has been a longstanding challenge in 
cardiovascular medicine. Canonical anti-inflammatory therapies, such as anti-tumor necrosis 
factor-α molecules/antibodies, to treat HFrEF have been abandoned.21 However, results 
from the CANTOS trial provided evidence that targeted “surgical strike” anti-inflammatory 
approaches have merit in cardiovascular disease.31 In the CANTOS trial, inhibition of 
interleukin-1 (IL-1) was able to lower the rate of recurrent cardiovascular events significantly 
compared with placebo independent of lipid lowering.31
This trial enrolled patients with prior myocardial infarction and high inflammatory burden—
as measured by increased circulating levels of high-sensitivity C-reactive protein—and did 
not provide specific evidence regarding the role of anti-IL-1 strategy in HF. However, it is 
conceivable that a similar strategy would confer benefit in patients suffering from different 
forms HF as well, and it will be of interest to design trials going forward to test this hypothesis.
Targeting IL-1 signaling has also been tested in HFpEF. Despite the fact that use of an IL-1 
receptor antagonist, Anakinra, seemed to ameliorate exercise intolerance in HFpEF patients, 




suggest that an approach targeting specific inflammatory pathways with a demonstrated 
role in HFpEF pathophysiology, rather than a broad strategy of cytokine antagonism, is 
warranted. For example, we have recently demonstrated that activation of the inflammatory 
molecule inducible nitric oxide synthase (iNOS) occurs in both preclinical and clinical HFpEF 
serving as a major source of nitrosative stress.23 Further, pharmacological inhibition or 
genetic deletion of iNOS greatly ameliorates the HFpEF syndrome in mice. Based on this, the 
availability of clinically approved iNOS inhibitors heralds promise as a therapeutic approach 
in HFpEF.23 Further investigation into molecular mechanisms of immune/inflammatory 
activation in HFpEF will likely reveal novel targets with potential clinical efficacy (Figure 2).
Therapeutic modulation of metabolism
Drugs targeting metabolic pathways can be effective in metabolic disease. For example, 
metformin, a modulator of the key cellular metabolism molecule AMP-activated protein 
kinase, is widely and effectively used in type II diabetes and recently has been shown to 
afford benefit in a preclinical model of HFpEF, ameliorating skeletal muscle dysfunction and 
exercise intolerance.34 However, pharmacological targeting of specific metabolic alterations 
in HFpEF is still underdeveloped. We and others have shown that one of the key metabolic 
alterations observed in HFpEF (and HF in general) is reduced bioavailability of nicotinamide 
adenine dinucleotide (NAD+), a required cofactor for sirtuin activity.35,36 We have demonstrated 
that reduced mitochondrial FA oxidation in HFpEF is, at least in part, dependent on 
hyperacetylation of key mitochondrial enzymes that, in turn, stems from NAD+ deficiency-
derived suppression of sirtuin activity.35 This mechanism raises the interesting prospect of 
pharmacologically boosting cardiac NAD+ levels to achieve benefits in HFpEF. Indeed, oral 
supplementation of nicotinamide riboside (NR), a NAD+ precursor, increased tissue NAD+ 
levels and ameliorates the HFpEF phenotype in rodents.35 Importantly, dietary supplementation 
with NR has been shown to increase NAD+ levels in humans, providing for potentially rapid 
translation of these results into clinical settings. Clinical trials testing the efficacy of NR in 
HFrEF are already ongoing, and a similar approach in HFpEF is foreseen (Figure 2).
CONCLUSIONS AND PERSPECTIVES
Cardiometabolic HFpEF is arguably the most prevalent form of HF. The increasing prevalence 
of this syndrome, coupled with the lack of efficacious therapeutic options, mandates 
intensification of research into the syndrome. Despite the existence of multiple HFpEF 
phenotypes, our increasing appreciation of molecular mechanisms of cardiometabolic 
alterations represents a major step forward toward emergence of specific therapeutic 
approaches for this syndrome.
Indeed, metabolic alterations and inflammatory burden are emerging as major 
pathophysiological mechanisms in this syndrome. As mentioned, inflammation rewires 
cellular metabolism, and systemic and local metabolic changes dictate immune cell behavior 
in HFpEF heart. These mechanisms occur not only in cardiomyocytes but in virtually all 
cardiac cells (i.e., endothelial cells, fibroblasts etc.) highlighting the complex interplay 
of meta-inflammatory mechanisms participating in HFpEF pathophysiology. It is worth 
mentioning that medications that have been provisionally shown to confer benefit in HFpEF 
specifically target metabolic pathways. We submit that enhanced, empirically driven, 
elucidation of biological mechanisms underlying cardiometabolic HFpEF is needed to move 
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